This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on ISI (2)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA

Underuse of -Blockers Following Myocardial Infarction

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: The article by Dr Phillips and colleagues,¹ which estimated the cost-effectiveness of -blocker therapy in all patients with myocardial infarction, adds to literature documenting poor health outcomes associated with underuse of -blockers.² Although we agree with the conclusions that increased -blocker use would lead to impressive gains in health, we believe that the authors neglected to consider the costs of program implementation in their analysis.

Although the efficacy of -blockers has been known for more than 2 decades, -blockers continue to be underprescribed, even for ideal candidates.³ The authors point out that the reasons for underuse of -blocker therapy are complex and that multiple strategies would be required to increase -blocker utilization to target levels. However, the authors do not address the costs of such strategies in their analysis. Costs associated with measures to increase -blocker usage would likely include quality improvement initiatives, multidisciplinary team approaches, or . . . [Full Text of this Article]

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Evidence-based vs. 'impressionist' medicine: how best to implement guidelines
Bassand et al.
Eur Heart J 2005;26:1155-1158.
ABSTRACT | FULL TEXT